Johnson & Johnson, BMS fight US drug price plan at Third Circuit

16 July 2024 - Pharmaceutical giants Johnson & Johnson, BMS and AstraZeneca are rejecting federal district court decisions that rule ...

Read more →

Submission of Nidlegy marketing authorisation application validated by EMA

4 July 2024 - The assessment period of the dossier by the authorities has started on 20 June. ...

Read more →

Hinova Pharmaceuticals receives FDA fast track designation for HP518 for treatment of androgen receptor triple-negative breast cancer

5 July 2024 - Hinova Pharmaceuticals today announced that the US FDA has granted fast track designation for HP518, an investigational ...

Read more →

Public Summary Documents – March 2024 PBAC meeting (round 1)

5 July 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2024 PBAC ...

Read more →

An online pharmacy pledged to make prescriptions easier. It sent the wrong drugs instead.

4 July 2024 - Elevance’s CarelonRx customers waited weeks for prescriptions or received medications that could have harmed them. ...

Read more →

CSL Behring announces first two patients treated with Hemgenix (etranacogene dezaparvovec) gene therapy for haemophilia B in Europe

4 July 2024 - CSL Behring today announced that two haemophilia B patients were treated with the gene therapy Hemgenix ...

Read more →

Tagrisso with the addition of chemotherapy approved in the EU as new first-line treatment for patients with EGFR-mutated advanced lung cancer

5 July 2024 - Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly ...

Read more →

Dutch Minister plans to implement new reimbursement system for high cost medicine

27 June 2024 - Concerns have been raised about the relative effectiveness of an increasing number of new medicines at ...

Read more →

PHARMAC opens first consultation for cancer medicines after funding boost

5 July 2024 - PHARMAC is looking to widen access to four medicines as part of the first public consultation ...

Read more →

RSV vaccination: protecting older people from serious complications

4 July 2024 - Referred by the Ministry of Health, the High Authority for Health has assessed the opportunity to integrate ...

Read more →

Gyre Therapeutics announces China’s NMPA approval of avatrombopag maleate tablets for the treatment of CLD associated thrombocytopenia

2 July 2024 - Gyre Therapeutics today announced that China’s National Medical Products Administration has approved Gyre Pharmaceuticals’ avatrombopag maleate tablets ...

Read more →

St Vincent’s splits with insurer NIB amid private hospitals ‘crisis’

4 July 2024 - Australia’s largest non-profit hospital operator says Labor is yet to fully grapple with a crisis facing ...

Read more →

Lisocabtagene maraleucel for the treatment of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

4 July 2024 - NICE is unable to make a recommendation on the use of lisocabtagene maraleucel (Breyanzi) in the NHS ...

Read more →

Checkpoint Therapeutics announces biologics license application resubmission for cosibelimab

2 July 2024 - Checkpoint Therapeutics today announced it has completed the resubmission of its biologics license application to the US ...

Read more →

Zilucoplan for the treatment of patients with generalised antibody positive myasthenia gravis

4 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...

Read more →

Hutchmed announces NDA acceptance in China for tazemetostat for the treatment of relapsed or refractory follicular lymphoma with priority review status

4 July 2024 - - Hutchmed (China) today announces that the new drug application for tazemetostat for the treatment of ...

Read more →